{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:27:45Z","timestamp":1772789265716,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14993-y","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:12:13Z","timestamp":1755151933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Extensive digital health technology assessment detects subtle motor impairment in mild and asymptomatic Pompe disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Andrea","family":"Pilotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Labella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rizzardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Zatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Trasciatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbin","family":"Romijnders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Geritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Caria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Risi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Damioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano Cotti","family":"Piccinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Ferullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loris","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Maetzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"14993_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","volume":"6","author":"JA Lim","year":"2014","unstructured":"Lim, J. A., Li, L. & Raben, N. Pompe disease: from pathophysiology to therapy and back again. Front. Aging Neurosci. 6, 177. https:\/\/doi.org\/10.3389\/fnagi.2014.00177 (2014).","journal-title":"Front. Aging Neurosci."},{"issue":"9","key":"14993_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/biom13091279","volume":"13","author":"B Labella","year":"2023","unstructured":"Labella, B. et al. A comprehensive update on Late-Onset Pompe disease. Biomolecules 13 (9), 1279. https:\/\/doi.org\/10.3390\/biom13091279 (2023).","journal-title":"Biomolecules"},{"key":"14993_CR3","doi-asserted-by":"publisher","unstructured":"Kishnani, P. S. et al. Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile- onset Pompe disease. Neurology. 68(2):99\u2013109 (2007). https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04. Erratum in: Neurology. 71(21):1748 (2008).","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"issue":"4","key":"14993_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/archneur.1972.00490100074007","volume":"26","author":"C Angelini","year":"1972","unstructured":"Angelini, C. & Engel, A. G. Comparative study of acid Maltase deficiency. Biochemical differences between infantile, childhood, and adult types. Arch. Neurol. 26 (4), 344\u2013349. https:\/\/doi.org\/10.1001\/archneur.1972.00490100074007 (1972).","journal-title":"Arch. Neurol."},{"issue":"23","key":"14993_CR5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus, E. et al. Long-term benefit of enzyme replacement therapy in Pompe disease A 5-year prospective study. Neurology 89 (23), 2365\u20132373. https:\/\/doi.org\/10.1212\/WNL.0000000000004711 (2017).","journal-title":"Neurology"},{"issue":"19","key":"14993_CR6","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar, L. et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology 93 (19), e1756\u2013e1767. https:\/\/doi.org\/10.1212\/WNL.0000000000008441 (2019).","journal-title":"Neurology"},{"key":"14993_CR7","doi-asserted-by":"publisher","unstructured":"Diaz-Manera, J. & COMET Investigator Group. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe Disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20(12):1012\u20131026 (2021). https:\/\/doi.org\/10.1016\/S1474-4422(21)00241-6. Erratum in: Lancet Neurol. 21(4):e4 (2022).","DOI":"10.1016\/S1474-4422(21)00241-6"},{"issue":"5","key":"14993_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/WCO.0000000000001092","volume":"35","author":"B Schoser","year":"2022","unstructured":"Schoser, B. & Laforet, P. Therapeutic thoroughfares for adults living with Pompe disease. Curr. Opin. Neurol. 35 (5), 645\u2013650. https:\/\/doi.org\/10.1097\/WCO.0000000000001092 (2022).","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"14993_CR9","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.4081\/ejtm.2021.9798","volume":"31","author":"C Angelini","year":"2021","unstructured":"Angelini, C. Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC consortium. Eur. J. Transl Myol. 31 (2), 9798. https:\/\/doi.org\/10.4081\/ejtm.2021.9798 (2021).","journal-title":"Eur. J. Transl Myol"},{"issue":"10","key":"14993_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1038\/s41591-023-02459-5","volume":"29","author":"L Servais","year":"2023","unstructured":"Servais, L. et al. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD. Nat. Med. 29 (10), 2391\u20132392. https:\/\/doi.org\/10.1038\/s41591-023-02459-5 (2023).","journal-title":"Nat. Med."},{"issue":"4","key":"14993_CR11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s13311-020-00901-x","volume":"17","author":"CA Artusi","year":"2020","unstructured":"Artusi, C. A. et al. Implementation of mobile health technologies in clinical trials of movement disorders: underutilized potential. Neurotherapeutics 17 (4), 1736\u20131746. https:\/\/doi.org\/10.1007\/s13311-020-00901-x (2020).","journal-title":"Neurotherapeutics"},{"issue":"4","key":"14993_CR12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/ene.15235","volume":"29","author":"S Bortolani","year":"2022","unstructured":"Bortolani, S. et al. Technology outcome measures in neuromuscular disorders: A systematic review. Eur. J. Neurol. 29 (4), 1266\u20131278. https:\/\/doi.org\/10.1111\/ene.15235 (2022).","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"14993_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.nmd.2012.10.024","volume":"23","author":"NA Van der Beek","year":"2013","unstructured":"Van der Beek, N. A., Hagemans, M. L., van der Ploeg, A. T., van Doorn, P. A. & Merkies, I. S. The Rasch- built Pompe-specific activity (R-PAct) scale. Neuromuscul. Disord. 23 (3), 256\u2013264. https:\/\/doi.org\/10.1016\/j.nmd.2012.10.024 (2013).","journal-title":"Neuromuscul. Disord"},{"key":"14993_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41746-019-0143-8","volume":"2","author":"A Hamed","year":"2019","unstructured":"Hamed, A., Curran, C., Gwaltney, C. & DasMahapatra, P. Mobility assessment using wearable technology in patients with late-onset Pompe disease. NPJ Digit. Med. 2, 70. https:\/\/doi.org\/10.1038\/s41746-019-0143-8 (2019).","journal-title":"NPJ Digit. Med."},{"issue":"1","key":"14993_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12877-020-1445-z","volume":"20","author":"J Geritz","year":"2020","unstructured":"Geritz, J. et al. Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn- study. BMC Geriatr. 20 (1), 45. https:\/\/doi.org\/10.1186\/s12877-020-1445-z (2020).","journal-title":"BMC Geriatr."},{"key":"14993_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fneur.2017.00457","volume":"8","author":"M Pham","year":"2017","unstructured":"Pham, M. et al. Validation of a step detection algorithm during straight walking and turning in patients with parkinson\u2019s disease and older adults using an inertial measurement unit at the lower back. Front. Neurol. 8, 457. https:\/\/doi.org\/10.3389\/fneur.2017.00457 (2017).","journal-title":"Front. Neurol."},{"key":"14993_CR17","doi-asserted-by":"publisher","first-page":"1279722","DOI":"10.3389\/fnagi.2023.1279722","volume":"15","author":"A Pilotto","year":"2023","unstructured":"Pilotto, A. et al. Unsupervised but not supervised gait parameters are related to fatigue in parkinson\u2019s disease: a pilot study. Front. Aging Neurosci. 15, 1279722. https:\/\/doi.org\/10.3389\/fnagi.2023.1279722 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"14993_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12984-019-0494-z","volume":"16","author":"A Paraschiv-Ionescu","year":"2019","unstructured":"Paraschiv-Ionescu, A. et al. Locomotion and Cadence detection using a single trunk-fixed accelerometer: validity for children with cerebral palsy in daily life-like conditions. J. Neuroeng. Rehabil. 16, 24. https:\/\/doi.org\/10.1186\/s12984-019-0494-z (2019).","journal-title":"J. Neuroeng. Rehabil"},{"issue":"7","key":"14993_CR19","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.3390\/s21072292","volume":"21","author":"J Welzel","year":"2021","unstructured":"Welzel, J. et al. Step length is a promising progression marker in parkinson\u2019s disease. Sens. (Basel). 21 (7), 2292. https:\/\/doi.org\/10.3390\/s21072292 (2021).","journal-title":"Sens. (Basel)"},{"key":"14993_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neubiorev.2015.11.014","volume":"61","author":"J Van Uem","year":"2016","unstructured":"Van Uem, J. et al. Health-Related quality of life in patients with parkinson\u2019s disease\u2013 A systematic review based on the ICF model. Neurosci. Biobehav Rev. 61, 26\u201334. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.11.014 (2016).","journal-title":"Neurosci. Biobehav Rev."},{"issue":"1","key":"14993_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41531-024-00682-6","volume":"10","author":"C Zatti","year":"2024","unstructured":"Zatti, C. et al. Turning alterations detected by mobile health technology in idiopathic REM sleep behavior disorder. NPJ Parkinsons Dis. 10 (1), 64. https:\/\/doi.org\/10.1038\/s41531-024-00682-6 (2024).","journal-title":"NPJ Parkinsons Dis."},{"issue":"1","key":"14993_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12984-020-00692-4","volume":"17","author":"A Atrsaei","year":"2020","unstructured":"Atrsaei, A. et al. Postural transitions detection and characterization in healthy and patient populations using a single waist sensor. J. Neuroeng. Rehabil. 17 (1), 70. https:\/\/doi.org\/10.1186\/s12984-020-00692-4 (2020).","journal-title":"J. Neuroeng. Rehabil"},{"issue":"1","key":"14993_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12883-017-0983-2","volume":"17","author":"B Schoser","year":"2017","unstructured":"Schoser, B. et al. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol. 17 (1), 202. https:\/\/doi.org\/10.1186\/s12883-017-0983-2 (2017).","journal-title":"BMC Neurol."},{"issue":"9","key":"14993_CR24","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1212\/01.wnl.0000142597.69707.78","volume":"63","author":"ML Hagemans","year":"2004","unstructured":"Hagemans, M. L. et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63 (9), 1688\u20131692. https:\/\/doi.org\/10.1212\/01.wnl.0000142597.69707.78 (2004).","journal-title":"Neurology"},{"key":"14993_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1750-1172-8-160","volume":"8","author":"R Lachmann","year":"2013","unstructured":"Lachmann, R. & Schoser, B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J. Rare Dis. 8, 160. https:\/\/doi.org\/10.1186\/1750-1172-8-160 (2013).","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"14993_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13023-024-03156-3","volume":"19","author":"KG Claeys","year":"2024","unstructured":"Claeys, K. G. et al. Minimal clinically important differences in six-minute walking distance in late- onset Pompe disease. Orphanet J. Rare Dis. 19 (1), 154. https:\/\/doi.org\/10.1186\/s13023-024-03156-3 (2024).","journal-title":"Orphanet J. Rare Dis."},{"issue":"15","key":"14993_CR27","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Van der Ploeg","year":"2010","unstructured":"Van der Ploeg, A. T. et al. A randomized study of alglucosidase Alfa in late-onset pompe\u2019s disease. N Engl. J. Med. 362 (15), 1396\u20131406. https:\/\/doi.org\/10.1056\/NEJMoa0909859 (2010).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"14993_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13023-021-02067-x","volume":"16","author":"A Hamed","year":"2021","unstructured":"Hamed, A. et al. Qualitative interviews to improve patient-reported outcome measures in late- onset Pompe disease: the patient perspective. Orphanet J. Rare Dis. 16 (1), 428. https:\/\/doi.org\/10.1186\/s13023-021-02067-x (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"14993_CR29","doi-asserted-by":"publisher","unstructured":"Kishnani, P. S. et al. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurol. Jun 1;80(6):558\u2013567. (2023). https:\/\/doi.org\/10.1001\/jamaneurol.2023.0552","DOI":"10.1001\/jamaneurol.2023.0552"},{"issue":"2","key":"14993_CR30","doi-asserted-by":"publisher","first-page":"108121","DOI":"10.1016\/j.ymgme.2023.108121","volume":"141","author":"A Toscano","year":"2024","unstructured":"Toscano, A. et al. Effect of avalglucosidase Alfa on disease-specific and general patient-reported outcomes in treatment-na\u00efve adults with late-onset Pompe disease compared with alglucosidase Alfa: meaningful change analyses from the phase 3 COMET trial. Mol. Genet. Metab. 141 (2), 108121. https:\/\/doi.org\/10.1016\/j.ymgme.2023.108121 (2024).","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"14993_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3233\/JND","volume":"10","author":"T Maulet","year":"2023","unstructured":"Maulet, T. et al. Determinants and characterization of locomotion in adults with Late-Onset Pompe disease: new clinical biomarkers. J. Neuromuscul. Dis. 10 (5), 963\u2013976. https:\/\/doi.org\/10.3233\/JND- (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"14993_CR32","doi-asserted-by":"publisher","first-page":"105277","DOI":"10.1016\/j.nmd.2025.105277","volume":"47","author":"M Porcino","year":"2025","unstructured":"Porcino, M. et al. Management of presymptomatic juvenile patients with late-onset Pompe disease (LOPD). Neuromuscul. Disord. 47, 105277. https:\/\/doi.org\/10.1016\/j.nmd.2025.105277 (2025).","journal-title":"Neuromuscul. Disord"},{"issue":"5","key":"14993_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S1474-4422(19)30397-7","volume":"19","author":"E Warmerdam","year":"2020","unstructured":"Warmerdam, E. et al. Long-term unsupervised mobility assessment in movement disorders. Lancet Neurol. 19 (5), 462\u2013470. https:\/\/doi.org\/10.1016\/S1474-4422(19)30397-7 (2020).","journal-title":"Lancet Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14993-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14993-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14993-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T18:03:11Z","timestamp":1755194591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14993-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14993-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Pilotto received grant support from Airalzh Foundation AGYR2021 Life-Bio Grant, The LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast, the H2020 IMI IDEA-FAST (ID853981), Italian Ministry of Health, Grant\/Award Number: RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110.Walter Maetzler receives or received funding from the European Union, the German Federal Ministry of Education of Research, German Research Council, Michael J. Fox Foundation, Neuroalliance, Lundbeck, Sivantos and Janssen. He received speaker honoraria from Abbvie, Bayer, BIAL, GlaxoSmithKline, Heel, Licher MT, R\u00f6lke Pharma, Takeda and UCB, was invited to Advisory Boards\/Consultancies of Abbvie, Aptar Digital Health, Atheneum, Biogen, Kyowa Kirin, Lundbeck and Pfizer, is an advisory board member of the Critical Path for Parkinson\u2019s Consortium and the MDS e-Diary Working Group, and an editorial board member of Geriatric Care. He is a member of the MDS Technology Working Group.Alessandro Padovani received grant support from Ministry of Health (MINSAL) and Ministry of Education, Research and University (MIUR), IMI H2020 initiative (IMI2-2018-15-06).Massimiliano Filosto received grant support from Telethon Italy Foundation and Italian Ministry of University and Research PRIN PNRR 2022.The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics Committee approved the Brescia Hospital\u2019s research protocol (NP 3710). Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}}],"article-number":"29798"}}